Potential Xyrem REMS Changes Could Invite Generics

Jazz Pharmaceuticals told investors Monday it expects the FDA to require modifications to the current risk evaluation and mitigation strategy (REMS) for its highly controlled narcolepsy drug Xyrem, a move some analysts say could expand market opportunities for generic competitors.
Drug Industry Daily